Posted by Michael Wonder on 13 Jan 2016
ERC recommends Jakavi for patients with polycythema vera who are resistant to or intolerant of hydroxyurea
7 January 2016 - The ERC has recommended the funding of ruxolitinib phosphate (Jakavi) so long as its cost-effectiveness is improved to an acceptable level.
For more details, go to: https://www.cadth.ca/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_in_rec.pdf
